Éñ¾­Éú³¤Òò×ÓÊÜÌåTrkAÔÚÖÐÊàÉñ¾­ÏµÍ³µÄ±í´ï¡¢·Ö²¼ºÍ×÷ÓÃ

À´Ô´£ºÑ°Ò½ÎÊÒ©Íø¡¡Ñ°Ò½ÎÊÒ©Íø

ÍÆ¼öÔĶÁ
     µËС»ª(×ÛÊö) ÂÞѧ¸Û(ÉóУ) 2004-8-8 14:10:44 ¹úÍâҽѧÉñ¾­²¡Ñ§Éñ¾­Íâ¿ÆÑ§·Ö²á2000ÄêµÚ27¾íµÚ1ÆÚ

    Õª Òª ÀÒ°±Ëἤø(tyrosine kinase,TrkA)ÊÇÉñ¾­Éú³¤Òò×Ó(nerve growth factor,NGF)µÄ¹¦ÄÜÐÔÊÜÌå¡£µ¨¼îÒÒõ£»¯×ªÒÆÃ¸(choline acetyltransferase,ChAT)Êǵ¨¼îÄÜÉñ¾­µÝÖÊÒÒõ£µ¨¼îºÏ³ÉµÄ¹Ø¼üø¡£´óÊó·¢Óý¹ý³ÌÖлùµ×ǰÄÔTrkA¡¢ChAT±í´ïÓÐÒ»¶¨µÄ¹æÂÉ£¬ÀÏÁäÊóºÍÔçÀÏÐÔ³Õ´ô²¡ÈË»ùµ×ǰÄÔTrkA¡¢ChAT±í´ïÃ÷ÏÔϵ÷¡£TrkA¡¢ChAT´Æ¼¤ËØÊÜÌå¹²´æÓÚ»ùµ×ǰÄÔÉñ¾­Ôª¡£´ÆÐÔ¼¤ËضÔÓÚ´óÊó»ùµ×ǰÄÔTrkA¡¢ChATά³ÖÕý³£µÄˮƽ·¢»Ó×÷ÓᣴÆÐÔ¼¤ËØÌæ´úÖÎÁƾø¾­ºóµÄ¸¾Å®ÓÐÖúÓÚ¼õÉÙÆä»¼°¢¶û´Äº£Ä¬²¡µÄ¿ÉÄÜÐÔ¡£

    ¹Ø¼ü´Ê£ºTrkA ChAT »ùµ×ǰÄÔ °¢¶û´Äº£Ä¬²¡ ´Æ¼¤ËØ

    Éñ¾­Éú³¤Òò×Ó(nerve growth factor,NGF)ÊÇÒ»ÖÖ¾­µäµÄÉñ¾­ÓªÑøÒò×Ó¡£NGFÔÚÖÜΧÉñ¾­ÏµÍ³(peripheral nervous system,PNS)²ÎÓë½»¸ÐÉñ¾­Ôª¡¢Éñ¾­áÕÆðÔ´µÄ¸Ð¾õÉñ¾­ÔªµÄ·¢Óý¡¢´æ»î£¬Î¬³Ö¼°ËðÉËÐÞ¸´µÈ×÷ÓÃÒÑÖð½¥ÎªÈËÃÇËùÈÏʶ¡£°ËÊ®ÄêÒÔºó£¬ÈËÃÇ·¢ÏÖNGF¶ÔÖÐÊàÉñ¾­ÏµÍ³(certral nervous system,CNS)Öлùµ×ǰÄÔ(basal forebrain)µ¨¼îÄÜÉñ¾­ÔªÓÐ×÷Ó᣶ø×÷ÓÃÓڸò¿µ¨¼îÄÜÉñ¾­ÔªµÄNGFÖ÷ÒªÓɰÐÇø(º£Âí¼°ÐÂÆ¤ÖÊ)²úÉú£¬¾­ÄæÐÐÔËÊäµ½µ¨¼îÄÜÉñ¾­Ôª°ûÌ壬·¢»ÓÆä°ÐÔ´ÐÔÓªÑø×÷ÓᣴóÁ¿µÄÑо¿±íÃ÷ÕâÀàÉñ¾­ÔªÑÇȺÔÚѧϰºÍ¼ÇÒäÖоßÓÐÌØÊ⹦ÄÜ¡£

    ÔÚÅàÑøPC12ϸ°ûµÄÅàÑø»ùÖмÓÈëNGFʱ£¬ÄÜÓÕµ¼PC12Í»ÆðµÄÉú³¤²¢Ê¹Ã¸µÄ»îÐÔÌá¸ß£¬µ«µ±×¢ÉäNGFµ½PC12ϸ°ûÌå»ò°ûºËʱ£¬²¢²»·¢ÉúÒÔÉϱ仯£¬´Ó¶øËµÃ÷NGFÉúÀí¹¦Äܵįô¶¯ÊÇÓÉĤÊÜÌå½éµ¼µÄ¡£½øÒ»²½Ñо¿·¢ÏÖ£¬NGFЧӦϸ°ûĤÉÏÓÐÁ½ÖÖÊÜÌåÀàÐÍ£¬¸ù¾ÝÆä¶ÔNGFµÄÇ׺ÍÐÔ·ÖΪ¸ßÇ׺ÍÁ¦ÊÜÌå(high affinity receptor,HNGFR)ºÍµÍÇ׺ÍÁ¦ÊÜÌå(low affinity receptor,LNGFR)¡£LNGFRÊÇÒ»ÖÖ¸»º¬°ëë×°±ËáµÄÌǵ°°×£¬Æä·Ö×ÓÁ¿Îª75kD,ËùÒÔÓÖ³Æp75¡£LNGFR°ûÖʲ¿·ÖûÓÐATP½áºÏλµã£¬ÖÂʹNGFÓëp75½áºÏºó²»ÄܻÄÚÔ´ÐÔ¼¤Ã¸£¬¹ÊNGFÓëp75µÄ½áºÏ²»ÄÜÖ±½Ó·¢»ÓÉúÎïѧЧӦ£¬µ«ÄÜͨ¹ýÔö¼ÓHNGFRÓëNGFµÄ½áºÏÂÊ£¬Ó°Ïìͨ¹ýHNGFR½øÐеÄÐźŴ«µÝ¡£1991ÄêKlein[1]µÈÑо¿·¢ÏÖHNGFRÊÇÓÉÀÒ°±Ëἤøԭ°©»ùÒò(tyrosine kinase proto-oncogene,TrK)±í´ïµÄÒ»ÖÖ¿çĤÌǵ°°×£¬·Ö×ÓÁ¿Îª140kD¡£ÏÖÒÑÖªHNGFRÖÁÉÙÓÐÒ»¸öÑÇ»ùÓÉTrkAÔ­°©»ùÒò±àÂë¡£TrkAÓÉÈý²¿·Ö×é³É£º¼´±æ±ð²¢½áºÏNGFµÄϸ°ûÍⲿ¡¢¿çĤ²¿¼°º¬ÀÒ°±ËἤøµÄ°ûÖʲ¿¡£TrkAÊÇNGFµÄ¹¦ÄÜÐÔÊÜÌ壬µ±ÆäÓëNGF½áºÏºó£¬¿É¼¤»îÀÒ°±ËἤøÐźŴ«µÝϵͳ£¬´Ó¶øÆô¶¯Ï¸°û»îÐÔ£¬²úÉúÉúÎïЧӦ¡£Boissiere[2]µÈÓÃÃâÒß×黯·½·¨¼ì²âÈË»ùµ×ǰÄÔ£¬·¢ÏÖ99%µ¨¼îÄÜÉñ¾­ÔªÓÐTrkA±í´ï£»ÓÐÈËÓÃԭλÔÓ½»ºÍÃâÒß×黯·½·¨·¢ÏÖTrkA mRNAºÍµ°°×Öʹ㷺µØ·Ö²¼ÓÚ´óÊóÖÐÊàÉñ¾­ÏµÍ³[3]¡£ÔÚ»ùµ×ǰÄÔ±í´ïTrkA mRNAµÄµ¨¼îÄÜÏËά¹ã·ºµØÍ¶Éäµ½º£ÂíºÍÐÂÆ¤ÖÊ¡£

    1 ·¢Óý¹ý³ÌÖлùµ×ǰÄÔTrkA±í´ïµÄ±ä»¯

    ÀûÓÃÃâÒß×黯·½·¨Ö¤ÊµÔÚ³ÉÄê´óÊó»ùµ×ǰÄԵĵ¨¼îÄÜÉñ¾­ÔªÓÐp75ºÍTrkAµÄ±í´ï[4]£¬ÓÐÈËÓÃÄæ×ªÂ¼¾ÛºÏøÁ´Ê½·´Ó¦(RT-PCR)̽¼°µ½ÅßÌ¥17Ìì´óÊó»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­ÔªÎÞTrkA mRNA±í´ï[5]£¬Éúºó3Ììµ½2Öܲŷ¢ÏÖÓÐTrkA mRNAµÄ±í´ï£»Li[6]µÈÓÃԭλÔÓ½»ºÍNorthernÓ¡¼£µÈ·½·¨¶¨Á¿·ÖÎöTrkA mRNA¡¢ChAT mRNAÔÚ´ó°×ÊóÅßÌ¥¡¢Éúºó¡¢³ÉÄê»ùµ×ǰÄÔÄÚ²à¸ôºË(MS)µÄ±ä»¯¡£·¢ÏÖÅßÌ¥17Ììʱ¾ùÎÞ±í´ï£¬Éúºó0ÌìÉÙÊý¼¸¸öϸ°û±í´ïTrkA mRNA¡¢ChAT mRNA£»Éúºó4ÌìÖÁ11Ì죬Á½Õß±í´ïÃ÷ÏÔÔö¼Ó£¬Éúºó21Ìì±í´ï×îÇ¿£¬¸ßÓÚ³ÉÄêÊóµÄˮƽ¡£Éúºó30Ìì³ÊϽµÇ÷ÊÆ£¬ÔÚ³ÉÄêÊóά³ÖÔÚÒ»¸öÏà¶ÔÎȶ¨±È½Ï¸ßµÄˮƽ¡£TrkA mRNAºÍChAT mRNAµÄ±í´ïÓÐÏàËÆµÄʱ¿Õģʽ¡£×î½üÓÐÈËÓÃÃâÒß×éÖ¯»¯Ñ§·½·¨¹Û²ìTrkA±í´ï£¬ÎÞChAT±í´ï£¬Éúºó5Ìì¿É¼ûChAT±í´ï£¬Éúºó20ÌìTrkA mRNA±í´ï´ï¸ß·å£»Éúºó30Ììϵ÷£¬³ÉÄêʱά³ÖÏà¶Ô½Ï¸ßˮƽ£¬ÀÏÄêʱTrkA mRNA±í´ïÃ÷ÏÔϵ÷¡£´óÊó»ùµ×ǰÄÔMeynert»ùµ×ºËTrkA±í´ïÔçÓÚChAT±í´ï¡£´ÓÉúºó5ÌìÆð£¬TrkA¡¢ChAT±í´ïÓÐÏàËÆµÄʱ¼äģʽ¡£TrkA¿ÉÄܲÎÓëMeynert»ùµ×ºËµ¨¼îÄÜÉñ¾­ÔªµÄ·¢Óý¡¢·Ö»¯¡¢³ÉÊì¡£NGF mRNA¡¢TrkA mRNAÔÚ·¢Óý¹ý³ÌÖеı仯¶ÔÓÚ»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­ÔªµÄ´æ»î¼°Í»ÆðÐγɿÉÄÜÆðÒ»¶¨µÄµ÷½Ú×÷Óá£ÔÚÄÔ·¢Óý²»Í¬½×¶Î»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­ÔªTrkA»ùÒò±í´ï¾ßÓн׶ÎÐÔ²îÒ죬Hsiang[7]µÈÓÃԭλÔÓ½»·½·¨·¢ÏÖ£¬ÔÚ³öÉúºó1Ìì´óÊó»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­ÔªÃ»Óв⵽TrkA»ùÒò£¬ÒÔºóÖð½¥Ôö¼Ó£¬4ÖÜʱ´ï×î¸ßˮƽ£¬ÕâÖÖ·¢Óý½×¶ÎµÄ±ä»¯Ó뺣Âí¼°Æ¤ÖÊÖÐNGF mRNA»ùÒò±í´ïµÄ±ä»¯ÓÐÆ½ÐйØÏµ[8]£¬ÌáʾNGF¶Ôµ¨¼îÄÜÉñ¾­Ôª·¢ÓýµÄµ÷¿Ø×÷Óã¬Ò²·´Ó¦ÁËÕâ¸ö¹ý³ÌÖÐNGFÊÜÌå¶ÔÕâÖÖµ÷¿ØµÄ²ÎÓë¡£

    2 ÀÏÁäÊóºÍ°¢¶û´Äº£Ä¬²¡(Alzheimer¡¯s disease,AD)²¡ÈË»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­ÔªTrkA¡¢ChAT±í´ïµÄ±ä»¯

    Cooper[9]µÈ½«125I-NGF×¢ÉäÈë³ÉÄê´óÊóºÍÀÏÁä´óÊó(26¡«30¸öÔÂ)º£ÂíÄÚ£¬·¢ÏÖÀÏÁäÊóÄÚ²à¸ôºËÄÜÉãÈ¡ºÍÄæÐÐת¶¯125I-NGFµÄChATÃâÒß·´Ó¦Éñ¾­ÔªÊýÄ¿¼õÉÙ31%£¬²»ÄÜÉãÈ¡ºÍÄæÐÐתÔË125I-NGFµÄµ¨¼îÄÜÉñ¾­ÔªÑÏÖØÎ®Ëõ¡¢°ûÌåµÄƽ¾ùÃæ»ý¼õÉÙ60%£¬Í¬Ê±£¬TrkA mRNA±í´ïϵ÷43%£¬¶øp75ûÓвîÒì¡£±íÃ÷ÀÏÁäÊó»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­ÔªÎ¬³ÖÊÜÌå½éµ¼°ÐÔ´ÐÔÉñ¾­ÓªÑøÒò×ÓµÄÉãÈ¡ºÍÄæÐÐתÔËÄÜÁ¦Ï½µ£¬µ¼ÖÂNGFÐźŴ«µÝ¹¦ÄÜÏ÷Èõ¡£Ôö¼ÓÁËÀÏÄ궯Îﵨ¼îÄÜÉñ¾­Ôª±äÐÔµÄÒ׸ÐÐÔ¡£×î½üÎÒÃÇÓÃÃâÒß×éÖ¯»¯Ñ§·½·¨·¢ÏÖÀÏÁäÊó(Meynert)»ùµ×ºË(basal nucleus of Meynert,nBM)TrkA¡¢ChAT-IRÉñ¾­ÔªÎ®Ëõ¡¢ÊýÁ¿·Ö±ð¼õÉÙ31.9%¡¢37.5%£»°ûÌ寽¾ù½ØÃæ»ý·Ö±ð¼õÉÙ39.4%¡¢30.4%£»Æ½¾ù»Ò¶È·Ö±ð¼õÉÙ11.8%¡¢9.9%¡£ÔçÀÏÐÔ³Õ´ôÊÇÓÉÓÚ»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­ÔªµÄ±äÐÔËÀÍö¼°ÏàӦƤÖÊ¡¢º£ÂíÉñ¾­ÔªÍË»¯ËùÒýÆðµÄÀÏÄêÉñ¾­ÔªÍËÐÐÐÔ¼²²¡£¬ÆäÖ÷ÒªÁÙ´²±íÏÖΪѧϰ¼°¼ÇÒ书ÄÜÕϰ­£¬µ¼ÖÂÑÏÖØµÄÖÇÁ¦µÍÏ¡£¶àÊýѧÕßÈÏΪAD²¡ÒòÖ÷ÒªÓëÒÒõ£µ¨¼îÄÜϵͳ¸Ä±äÓйء£Boissiere[10£¬11]µÈÓÃԭλÔÓ½»·½·¨·¢ÏÖAD²¡ÈËÓëÀÏÄêÈ˶ÔÕÕ×é±È½Ï£¬nBMµ¨¼îÄÜÉñ¾­ÔªTrkA mRNA±í´ï¼õÉÙ75%£¬²îÒìÓÐÏÔÖøÐÔ(P<0.001)£»¸¹²àÎÆ×´Ìå(ventral atriatum)TrkA mRNA±í´ï¼õÉÙ41%(P<0.01)¡£¶¹×´ºË¿Ç(putamen)TrkA mRNA±í´ï¼õÉÙ43%¡«53%(P<0.01)¡£Mufson[12]µÈÓÃԭλÔÓ½»·½·¨·¢ÏÖAD²¡ÈËÓëÀÏÄêÈ˶ÔÕÕ×é±È½Ï£¬nBMµ¨¼îÄÜÉñ¾­ÔªTrkA mRNA±í´ï¼õÉÙ66%£¬ÓÃÄæ×ªÂ¼¾ÛºÏøÁ´Ê½·´Ó¦(RT-PCR)·½·¨Ò²µÃ³öͬÑùµÄ½áÂÛ¡£½øÒ»²½ÓÃÃâÒß×黯·½·¨Ñо¿·¢ÏÖ£ºAD²¡ÈËnBMÄÚµ¨¼îÄÜÉñ¾­ÔªTrkAµ°°×Öʱí´ïÓëÀÏÄêÈ˶ÔÕÕ×é±È½Ï£¬AD²¡ÈËnBMÄÚÐÒ´æµÄTrkA iRÑôÐÔÉñ¾­ÔªÊýÁ¿¼õÉÙ60%£¬È¾É«ÃܶȼõÉÙ35%£¬Ï¸°ûÍâÐÎÖåËõ£¬Ê÷Í»½Ø¶Ï±äÐΣ¬Õû¸öϸ°û³ÊÖ×Õ͵ÄÇòÐÎÍâ¹Û(swollen globose appearance)[13]¡£

    3 TrkA¶ÔÓÚ»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­ÔªµÄ×÷ÓÃ

    Fagan[14]µÈ½«Ð¡Êó»ùµ×ǰÄÔ¡¢ÎÆ×´Ì嵨¼îÄÜÉñ¾­Ôª±àÂëTrkAÊÜÌåµÄ»ùÒòʧ»î(TrkA-/-)·¢ÏÖÉúºó7ÌìСÊó»ùµ×ǰÄÔ¡¢ÎÆ×´Ì嵨¼îÄÜÉñ¾­ÔªChAT-IRÑôÐÔ²úÎï°ûÌåµÄƽ¾ù½ØÃæ»ý¼õÉÙ10%¡«20%£»Éúºó20¡«25ÌìСÊóChAT-IRÑôÐÔÉñ¾­ÔªÊýÄ¿20%¡«36%£¬°ûÌåήËõ±äС£¬ChATÃâÒß·´Ó¦ÐÔ½µµÍ£¬°ûÌåºÍµ¨¼îÄÜÉñ¾­ÏËάձ±ê¼ÇÃܶȼõÉÙ£¬±íÃ÷ÕýÔÚ·¢ÓýµÄ(TrkA-/-)СÊ󵨼îÄÜÉñ¾­ÔªChAT±í´ï¼õÉÙ£¬×è°­·¢Óý³ÉÊì¡£½á¹û±íÃ÷ÕýÔÚ·¢Óý(TrkA-/-)СÊ󵨼îÄÜÉñ¾­ÔªChATµÄ±í´ï¼õÉÙ£¬Ï¸°ûËÀÍöÔö¼Ó¡£(TrkA-/-)СÊó»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­Ôª¶ªÊ§ÓëÉúºó1¡«4ÖÜʱ£¬°ÐÔ´ÐÔÉñ¾­ÓªÑøÒò×Óȱʧµ¼ÖÂϸ°ûËÀÍöÊÇÒ»ÖµÄ[15]¡£È±·¦TrkAÊÜÌ壬NGF²»ÄÜÓëÌØÒìÐÔµÄÊÜÌå½áºÏ£¬²»ÄܽøÐÐϸ°ûÄÚÐźŴ«µÝ£¬ÕýÔÚ·¢ÓýµÄ»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­Ôª²»Äܳä·ÖµØ·¢Óý³ÉÊì¡£

    4 TrkAÓëChAT¡¢´Æ¼¤ËØÊÜÌå(estrogen receptor,ER)¹²´æ

    Sobreviela[16]µÈÓÃÃâÒß×黯·½·¨·¢ÏÖ£ºÄÚ²à¸ôºËºÍб½Ç´øºËÄÚ95%ÒÔÉÏTrkAÃâÒß·´Ó¦ÑôÐÔÉñ¾­ÔªÄڼȺ¬ÓÐChATÒ²º¬ÓÐp75 nGFR£»Meynert»ùµ×ºËÄÚ80%ÒÔÉÏTrkAÃâÒß·´Ó¦ÑôÐÔÉñ¾­ÔªÄÚº¬ÓÐChAT£¬95%ÒÔÉϵÄTrkAÃâÒß·´Ó¦ÑôÐÔÉñ¾­ÔªÄÚº¬ÓÐp75¡£Gibbs[17]µÈÓÃÃâÒß×黯·½·¨Ö¤Ã÷50%¡«80%µÄµ¨¼îÄÜChATÃâÒß·´Ó¦Éñ¾­ÔªÄÚº¬ÓÐER£¬´ÆÐÔ´óÊó½ÏÐÛÐÔ´óÊó¶à10.5%¡£ÎÆ×´ÌåÄÚË«±êϸ°ûÕ¼74.2%£¬Ð±½Ç´øºËˮƽ֧ÄÚΪ63.4%¡£Toran[18£¬19]µÈÓ÷ÅÉä×ÔÏÔÓ°ºÍԭλÔÓ½»¡¢ÃâÒß×黯·½·¨·¢ÏÖ»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­Ôªº¬ÓдÆÐÔ¼¤ËصĸßÇ׺ÍÐÔÁ¬½Óλµã£¬¼´´Æ¼¤ËØÊÜÌ壬ÊôºËÊÜÌ壬ΪһºËת¼Òò×Ó¡£½á¹ûÌáʾËüÃǵÄÅäÌå(Éñ¾­ÓªÑøÒò×Ó¡¢´ÆÐÔ¼¤ËØ)¿ÉÄÜ×÷ÓÃÓÚͬһÉñ¾­Ôª£¬Ð­Í¬µ÷½Úϸ°ûÄÚÌØÒìµÄ»ùÒò»òÕß»ùÒòÍøÂçµÄ±í´ï¡£´Ó¶øµ÷¿ØmRNAµÄϸ°ûÄÚ×é³É£¬Ó°Ïìµ°°×ÖÊÉú³ÉµÄÁ¿¼°ÆäÐÔÖÊ£¬×îÖÕÓ°ÏìÉñ¾­ÔªµÄ´æ»î¡¢·Ö»¯¡¢ÔÙÉúºÍ¿ÉËÜÐÔ¡£

    5 ´ÆÐÔ¼¤ËضÔÓÚ»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­ÔªTrkA mRNAºÍChAT mRNA±í´ïµÄµ÷½Ú

    Pamela[20]µÈÈ˽«³ÉÄê´ó°×ÊóÂѳ²Çгýºó10Ì죬HDBºÍnBMÄÚTrkA mRNA±í´ïˮƽ·Ö±ðϵ÷56%ºÍ34%£¬¶øChAT mRNA·Ö±ðϵ÷38%¡«65%£¬ÓëGibbs[21]µÈÈËÑо¿½á¹ûÏàËÆ¡£´ÆÐÔ¼¤ËØÌæ´úÖÎÁÆ3Ììºó£¬TrkA mRNA¡¢ChAT mRNA±í´ï»Ö¸´µ½Î´ÇÐÂѳ²µÄ¶¯ÎïµÄˮƽ£¬¶øVDBÖеÄTrkA mRNA¡¢ChAT mRNA±í´ïûÓÐÃ÷ÏԵIJîÒì¡£Gibbs[22]µÈ¹Û²ìÊóÁä·Ö±ðΪ13¸öÔ¡¢19¸öÔºÍ25¸öÔµÄÐÛÐÔ¡¢´ÆÐÔ´óÊ󣬷¢ÏÖÄêÁä¶ÔÓÚMS¡¢nBMÄÚChAT¡¢p75ÃâÒß·´Ó¦ÑôÐÔÉñ¾­ÔªµÄϸ°û´óС¡¢ÏËάȾɫÃܶȵÄÓ°ÏìûÓÐÏÔÖøÐÔ²îÒ죬13¡«25¸öÔÂÁäÊóÖУ¬25¸öÔÂÁäÊóTrkA mRNAÃ÷ÏԵؼõÉÙ¡£½«13¸öÔÂÁäÊóÂѳ²Çгý6¸öÔºó£¬MS¡¢nBMÄÚTrkA mRNA¡¢ChAT mRNAÃ÷ÏԵؼõÉÙ£¬¶ÌÆÚÄÚ´ÆÐÔ¼¤ËØÌæ´úÖÎÁƺó£¬MS¡¢nBMÄÚTrkA mRNA¡¢ChAT mRNAÃ÷ÏԵؼõÉÙ£¬¶ÌÆÚÄÚ´ÆÐÔ¼¤ËØÌæ´úÖÎÁƺó£¬MS¡¢nBMÄÚTrkA mRNA¡¢ChAT mRNA²¿·Ö»Ö¸´¡£½á¹ûÌáʾÂѳ²·ÖÃڵĴƼ¤ËضÔÓÚ´ó°×Êó»ùµ×ǰÄÔMS¡¢nBMÄÚTrkA mRNA¡¢ChAT mRNAά³ÖÕý³£Ë®Æ½·¢»ÓÖØÒª×÷Óá£Âѳ²Çгýºó£¬MSºÍnBMÄÚTrkA mRNA±í´ï¼õÉÙ£¬¶ÔÓÚÄÚÔ´ÐÔµÄÉñ¾­Éú³¤Òò×ÓЧӦ½µµÍ£¬»ùµ×ǰÄÔ¶ÔÓÚË¥ÀϺͼ²²¡µÄÒ׸ÐÐÔÔö¼Ó£¬µ¨¼îÄÜÉñ¾­ÔªµÄ¹¦ÄÜϽµ¡£Òò´Ë£¬³¤ÆÚµÄÂѳ²¹¦ÄÜɥʧ£¬¶Ô»ùµ×ǰÄÔµ¨¼îÄÜÉñ¾­Ôª½«²úÉú²»ÀûÓ°Ïì¡£´ÆÐÔ¼¤ËØÌæ´úÖÎÁƾø¾­ºóµÄ¸¾Å®ÓÐÖúÓÚ¼õÉÙÆä»¼AD²¡µÄ¿ÉÄÜ¡£

    6 ´ÆÐÔ¼¤ËغÍNGFЭͬ×÷Ó㬿ÉÍûÓ¦ÓÃÓÚÁÙ´²

    ´ÆÐÔ¼¤ËØÄܹ»Éϵ÷Éñ¾­ÓªÑøÒò×ÓºÍËüÃǵÄÊÜÌåµÄ±í´ï£¬¶øNGFÄܹ»Ôö¼ÓChAT mRNAµÄÊýÁ¿£¬ÔöÇ¿ChATµÄ»îÐÔ£¬´Ó¶øÔö¼ÓAchµÄÊÍ·Å¡£´ÆÐÔ¼¤ËضÔÓÚµ¨¼îÄÜϵͳÉñ¾­ÔªµÄÓªÑø×÷ÓÿÉÄܲ¿·ÖµØ¾­¹ýÉñ¾­ÓªÑøÒò×ÓÓëÆäÊÜÌå½áºÏºó´«µÝÐÅÏ¢¶ø±»½éµ¼¡£GibbsµÈÑо¿·¢ÏÖ´ÆÐÔ¼¤ËصļÁÁ¿ºÍ¸øÒ©ÖÎÁƵÄÖÜÆÚ²»Í¬£¬Ëü¶ÔÉñ¾­ÓªÑøÒò×Ó»ùÒòÒÔ¼°ÊÜÌåµÄ±í´ïÓв»Í¬µÄЧ¹û¡£ÁÙ´²Ó¦ÓÃÖоø¾­ºóµÄ¸¾Å®ÓôÆÐÔ¼¤ËØÌæ´úÖÎÁÆ¿ÉÒÔÔ¤·ÀAD²¡µÄ·¢Éú[21]£¬µ«ÊÇÈéÏÙ°©·¢²¡ÂÊÃ÷ÏÔÔö¸ßÕâÒ»¸±×÷ÓÃÒ²²»ÈݺöÊÓ¡£´ÆÐÔ¼¤ËغÍNGFЭͬӦÓÃÓÚÁÙ´²»¹ÓдýÓÚ½øÒ»²½µÄ̽Ë÷¡£

    ²Î¿¼ÎÄÏ×

    1 Klein R,et al.Cell,1991;65:189

    2 Boissiere F,et al.C-R-Acad-Sci-¢ó£¬1994;37(11):997

    3 David M,et al.Cell,1991;65:189

    4 Steining TL,et al.Brain Res,1993;612:330

    5 Masami K,et al.Neuroscience Letters,1994;169:47

    6 Li Yiwen,et al.J Neurosci,1995;15(4):2888

    7 Hsiang J,et al.Neuroscience,1988;26:417

    8 Large TH,et al.Science,1986;234:352

    9 Cooper JD,et al.Neuroscience,1994;62(3):625

    10 Boissiere F,et al.Exp Neurol,1997;145(1):245

    11 Boissiere F,et al.Dement Geriatr Cogn Disord,1997;8:1

    12 Mufson EJ,et al.Neuroreport,1996;8:25

    13 Mufson EJ,et al.Exp Neurol,1997;146:91

    14 Fagan AM,et al.J Neurosci,1997;17(20):7644

    15 Crowley C,et al.Cell,1994;76:1001

    16 Sobreviela T,et al.J Comp Neurol,1994;350:587

    17 Gibbs RB.Brain Res,1996;720:61

    18 Toran-Allerand,et al.Proc Natl Acad Sci USA,1992;89:4668

    19 Miranda RC,et al.Horm Behav,1994;28:367

    20 Pamela J,et al.J Neurosci,1996;16:1860

    21 Gibbs RB,et al.Exp Neurol,1994;129:70

    22 Gibbs RB.Exp Neurol,1998;15:289
Ïà¹ØÎÊ´ð£º
  • ÉúÃüÌåÕ÷µÄ¸Ä±ä¶ÔÖÐÊàÉñ¾­ÏµÍ³µÄÓ°ÏìÊÇʲô.
  • ÊÓÁ¦Ë«Ó°¾­¼ì²éÊÇÖÐÊàÉñ¾­ÏµÍ³µÄÎÊÌâÓ¦Ôõô.
  • ÎÒÕâÊÇÉñ¾­ÏµÍ³µÄ²¡Âð£¿
  • ÊÇ·ñÓ°ÏìÖÐÊàÉñ¾­ÏµÍ³
  • Éñ¾­Éú³¤Òò×ÓµÄ×÷ÓÃÊÇʲô?
  • ÄÔÉñ¾­ÏµÍ³µÄ¼¸ÖÖ¼²²¡Ôõô´¦Àí
  • ÎÒÊÇ·ñµÃÁËÖ²ÎïÉñ¾­ÏµÍ³µÄ²¡£¿
  • ÖÐÊàÉñ¾­ÏµÍ³²¡¶¾¸ÐȾÓÐʲô֢״
  • ²»ÖªµÀÊÇÏû»¯ÏµÍ³»¹ÊÇÉñ¾­ÏµÍ³µÄÎÊÌâ¡­¡­
  • ÒòΪ¾«ÉñÉÏÊܵ½´Ì¼¤¶øÊ¹Éñ¾­ÏµÍ³µÄÓïÑÔÄÜÁ¦.

  • Ïà¹Ø×ÊѶ£º
  • ÖÐÊàÉñ¾­ÏµÍ³¼²²¡Ôì³ÉµÄÍÑ·¢
  • Îü¶¾¶ÔÉñ¾­ÏµÍ³µÄΣº¦
  • Ö¬·¾Èé¼ÁÖÂÖÐÊàÉñ¾­ÏµÍ³²»Á¼·´Ó¦
  • ÈËÌåÉñ¾­ÏµÍ³µÄÖ÷Òª×é³É
  • Éñ¾­ÏµÍ³µÄÒ©ÎïÖж¾¡ª¡ªÉöÉÏÏÙËØ
  • Éñ¾­ÏµÍ³µÄÒ©ÎïÖж¾¡ª¡ªÂ黯¼î
  • Îüʳ¶¾Æ·¶ÔÉñ¾­ÏµÍ³µÄΣº¦
  • È«¹úÖÐÊàÉñ¾­ÏµÍ³¼²²¡Ó°ÏñÕï¶Ï¼°Ð½øÕ¹Ñ§Ï°.
  • Îüʳ¶¾Æ·Î£º¦Éñ¾­ÏµÍ³
  • ÄÔºÍÉñ¾­ÏµÍ³ÊÇÔõÑùË¥ÀϵÄ
  • ½¡¿µÍ¼Æ×
    ½¡¿µÉ̳Çhttp://shop.xywy.com ½¡¿µ¹ºÎïºÃÈ¥´¦
    ÓÑÇéÁ´½Ó